Blood test may spot hidden cancers years early
NCT ID NCT04405557
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is testing whether a blood test that looks for tumor DNA (ctDNA) can detect six types of cancer early in people at high risk. About 757 participants aged 45 and older with certain risk factors are being monitored. The goal is to see how accurate the test is and how much time it gives before a standard diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test that catches several cancers earlier, when they may be easier to treat.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures how well ctDNA detects cancer; it does not prove that early detection improves outcomes. Results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 757 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2019
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
People with positive tumor protein marker or cancer screening.
- Ages
-
45 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged at or over 45 years old. 2. Patients who with one or more of the following situations: 1. In AFP (\>20UG/L), CA125 (\>70U/ml), CEA (\>7ng/ml) and CA199 (\>60U/ml), more than one item was abnormal for two consecutive times within one month. 2. Patients with viral hepatitis (Hepatitis B / C surface antigen positive with liver function damage. 3. Patients with liver nodules detected by ultrasound and hemangioma excluded. 4. Patients with compensated cirrhosis. 5. CA125\>35U/ml and HE4 was abnormal (the reference value of HE4 in premenopausal and postmenopausal women was 68.96 pmol/L and 114.90 pmol/L respectively). 6. Patients with ovarian masses found by ultrasonography (premenopausal \> 5cm, postmenopausal \> 3.5cm). 7. Patients with pancreatic space-occupying found by ultrasonography. 8. Patients with BI-RADS grade 4 or above by ultrasound or mammography. 9. CA125\>35U/ml and BI-RADS above grade 3 by ultrasound or mammography. 10. CA153\>25U/ml and BI-RADS above grade 3 by ultrasound or mammography. 11. Family genetic history of breast cancer and ovarian cancer, and BI-RADS above grade 3 by ultrasound or mammography. 12. Patients with a positive fecal occult blood test and haemorrhoids excluded 13. Patients with a positive fecal occult blood test and positive CEA 14. More than 2 items were abnormal in PGI, PGR and G-17 (criteria: PGI≤70 UG/L, PGR≤7.0, G-17≤1 pmol/L or G-17≥15 pmol/L). 3. Ability to collect specimens from each time point and provide corresponding clinical information. 4. Understand the research plan and voluntarily participate in the study, sign the informed consent form. Exclusion Criteria: 1. Patients with previous or present cancer. 2. Patients with serious diseases, especially those with a survival period of less than 3 years. 3. Patients with factors that affect the diagnosis of the disease (such as MRI related cardiac pacemakers, ferromagnetic implants, etc.). 4. Patients with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 5. Women who are pregnant or preparing for pregnancy. 6. Patients who voluntarily withdraw for any reason. 7. Patients who cannot complete the research plan
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Early detection of cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Union Hospital of Jilin University
Changchun, Jilin, 130033, China
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, 518020, China
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
-
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, 121001, China
-
Xiangya Hospital Central South University
Changsha, Hunan, 410008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can detailed test data help people decide on Multi-Cancer screening?
- Could a simple online course boost cancer screening in migrant women?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Can a simple MRI and blood test catch pancreatic cancer earlier?
- New strategies aim to boost lung cancer screening and save lives
- Could ultrasound screening catch breast cancer earlier in older women?